ADAPY

0.03003.23%
CJ

Christopher James Hill

CEO, CFO, Secretary & Director

Mr. Christopher James Hill, also known as Chris, BA (Hons), ACA, serves as Chief Financial Officer and Company Secretary at Abaco Capital plc (formerly known as Oxford Pharmascience Group Plc). He serves as Chief Financial Officer at Adaptimmune Therapeutics plc since September 10, 2025 and is its Chief Executive Officer, Secretary and Director from November 14, 2025. He serves as Chief Financial Officer at Istesso Limited since 2022. Mr. Hill has been Company Secretary at Quorum plc (Formerly Bluebird Energy plc) since January 2013 and serves as its Financial Controller since March 2013. Mr. Hill serves as finance director of Quorum plc since August 8, 2013. He was Finance Director at Abaco Capital plc (formerly known as Oxford Pharmascience Group Plc) since October 16, 2013. Mr. Hill joined the AIM listed investment company, ORA Capital Partners Ltd, as Group Financial Controller in 2010, where he was responsible for all aspects of financial management including statutory financial reporting, corporate transactions and fundraises. He is also a director of Quoram Plc. He has been a Director of Abaco Capital plc (formerly known as Oxford Pharmascience Group Plc) since October 17, 2013. He has been a Non-executive director of Quorum plc since August 8,2013. He B.A. in Economics and Public Policy from Leeds Metropolitan University where he combined his studies with a professional rugby career. He then went on to gain his professional accountancy qualification with Grant Thornton where he gained experience of a wide range of businesses from small private clients to full list PLC’s.

Positions